


## SUPPLEMENTARY MATERIAL



**Figure S1.** Protocol scheme of cytokines determination.

## REFERENCES

1. Peña, C. *et al.* Prospective multicenter study of the impact of carbapenem resistance on mortality in *Pseudomonas aeruginosa* bloodstream infections. *Antimicrob. Agents Chemother.* (2012) doi:10.1128/AAC.05991-11.
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. twenty-Fourth Informational Supplement. Document M100-S24. CLSI, Wayne, PA. (2014).
3. Smani, Y. *et al.* In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant *Acinetobacter baumannii*. *Clin. Microbiol. Infect.* (2012) doi:10.1111/j.1469-0691.2011.03695.x.
4. National Research Council. Guide for the Care and Use of Laboratory Animals: Eighth Edition. National Academies Press, Washington, DC, 2011.
5. Smani, Y., Domínguez-Herrera, J., Ibáñez-Martínez, J. & Pachón, J. Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* (2015) doi:10.1128/AAC.04986-14.
6. Parra Millán, R. *et al.* Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against *Acinetobacter baumannii* in experimental murine peritoneal sepsis and pneumonia models. *Antimicrob. Agents Chemother.* (2016) doi:10.1128/AAC.02708-15.
7. Ye, G. *et al.* Simultaneous determination of vancomycin and ceftazidime in cerebrospinal fluid in craniotomy patients by high-performance liquid chromatography. *J. Pharm. Biomed. Anal.* (2008) doi:10.1016/j.jpba.2008.06.012.
8. Usansky JL, Desai A, T.-L. D. PK Functions for Microsoft Excel, Allergan, Irvine, CA: Department of Pharmacokinetics and Drug Metabolism; USA. <https://www.boomer.org/pkin/soft.html> (2012).
9. Craig, W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin. Infect. Dis.* (1998).
10. Pachón-Ibáñez, M. E. *et al.* Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* (2010) doi:10.1128/AAC.00367-09.